Welcome to resTORbio
resTORbio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases.
The decline in immune function that occurs during aging, or immunosenescence, increases susceptibility to a variety of diseases that significantly contribute to morbidity and mortality in the elderly. resTORbio’s lead program has demonstrated in several clinical trials, including a randomized, placebo-controlled trial, the potential to treat multiple diseases of aging for which there are no approved therapies. resTORbio's approach focuses on the mechanistic target of rapamycin (mTOR) pathway, an evolutionarily conserved pathway that regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1, or TORC1. The Company's initial focus is on the development of RTB101, an orally administered, small molecule, potent TORC1 inhibitor, alone and in combination with other mTOR inhibitors such as everolimus, as a first-in-class immunotherapy program designed to improve immune function. The lead indication for the program is the reduction of incidence of respiratory tract infections, or RTIs, in the elderly regardless of the causative pathogen.
resTORbio's goal is to be a leading biopharmaceutical company focused on treating aging-related diseases.
Our Key Shareholders
Co-Founder, President and CEO
Abdellah Sentissi, Ph.D
Head of CMC and Pharmaceutical Development
Joan Mannick, M.D.
Co-Founder, Chief Medical Officer
Vice President of Regulatory Affairs